Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

0

0Neutropenic sepsis

0

0

1 (3%)

0Febrile neutropenia

0

0

1 (3%)

0Note: There were two possible treatment-related deaths: sepsis (q21d) and acute renal failure following diarrhea (q14d).  

Figure E: Safety Table: Other Safety-Neuropathy and AlopeciaNo grade 3 or 4 neuropathy was reported.NKTR-102

145 mg/m2

q14d

N=35

NKTR-102

145 mg/m2

q21d

N=35Grade 1

Grade 2

Grade 1

Grade 2Alopecia

6 (20%)

0

3 (9%)

1 (3%)About Metastatic Breast CancerMore than one million women worldwide are diagnosed with breast cancer globally every year(1).  The chance of developing invasive breast cancer at some time in a woman's life is a little less than one in eight (12%).  There are approximately 200,000 new cases of breast cancer in the United States and 430,000 in Europe each year.(2)  Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.  

Anthracyclines and taxanes (AT) are the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease.  Drugs used to treat patients who progress following AT treatment can have response rates as high as 20-30%; however, resistance develops rapidly and new agents with different mechanisms of action, such as topoisomerase I inhibitors, are needed to allow novel ways to overcome the problem of drug resistance. (3)  There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.

About NKTR-102 Nektar is developing NKTR-102, a next-generation topoisomerase I inhibitor with reduced peak concentrations and a continuous concentration profi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... not always keep hands injury-freeLAS VEGAS, Feb. 27 ... on the rise in recent years, with more than ... Many of those injuries might be prevented with better ... the 2009 Annual Meeting of the American Academy ...
... Fenofibrate treatment reduces,cardiovascular disease (CVD) ... the,composite of cardiovascular death, myocardial infarction, ... patients with type 2 diabetes and,atherogenic ... high triglyceride (2.3,mmol/L-200mg/dL or higher) and ...
Cached Medicine Technology:Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 2Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 3Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 5Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 6
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
(Date:12/24/2014)... December 25, 2014 BambooIndustry.com a famous ... many years. Today, the company announces its multiple ... special offer on these new products. , Bamboo panel ... bamboo. The multiple layer bamboo panel board features high ... strong and emissions free. The bamboo panel consists of ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Adults ... higher risk of migraine headaches, suggests a study ... Neurology . "Childhood maltreatment can have long-lasting ... migraine in adulthood," study author Dawn Buse, director ... New York City, said in a journal news ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... release is available in French . , ... Health Centre researchers has passed its first clinical trial with ... each individual patient, and was developed by Dr. J-P. Routy ... Dr. R. Skaly from the Universit de Montral. "This is ...
... ways to enjoy festive feasting , WEDNESDAY, Nov. 25 (HealthDay ... Thanksgiving to New Year,s, but are already stressing about the ... help is at hand. , It,s possible, say nutrition experts, ... 2010 weighing the same as you do today. , ...
... ... News/ EIN News, an online leader in industry news monitoring and ... analysts: H1N1 News Today ( http://h1n1.einnews.com ). , ... epidemic from governments, news outlets and research centers the world over, ...
... Senior doctors from across the globe have come together to ... to mobilise health professionals across the world to help tackle ... be officially launched on Wednesday 25 November 2009 to coincide ... Lancet on the public health impact of strategies to ...
... , ... Americans are afflicted with sinusitis. A clinically proven, minimally invasive technology for treating chronic ... system by Acclarent™ uses a small catheter and balloon to quickly open and expand ... ...
... ... plastic surgeon in Richmond , is launching a new website utilizing the latest ... site incorporates a variety of media platforms to create an interactive web experience that’s ... , ...
Cached Medicine News:Health News:Tailor-made HIV/AIDS treatment closer to reality 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3Health News:H1N1 News Today Examines the Swine Flu Virus From a Global Perspective; Read the Latest H1N1 Virus Vaccine & Prevention News From EIN News 2Health News:Senior doctors launch global movement to tackle climate change 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 2Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 3Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 4
... innovative design, the Burton 7500-I refractor delivers ... At Burton, we set out not only ... innovative concept, but to set the industry ... and stringent testing, we devote more resources ...
... year warranty Set one of two memory ... exam!, One touch auto return button, Durable ... colors , Solid-State push button control panel ... transformer. , Electro-Magnetic counter-balanced slit lamp arm ...
Our 2.5v Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
... technological innovation are standard in all ... for Optometry students, the 18335-SDS combines ... Coaxial-Plus Ophthalmoscope, the superior illumination of ... halogen illumination of the Finnoff Transilluminator, ...
Medicine Products: